The ocular benefits of estrogen replacement therapy: a population-based study in postmenopausal Korean women
Type of Spiritual Experience
A description of the experience
PLoS One. 2014 Sep 11;9(9):e106473. doi: 10.1371/journal.pone.0106473. eCollection 2014.
The ocular benefits of estrogen replacement therapy: a population-based study in postmenopausal Korean women.
Na KS1, Jee DH1, Han K2, Park YG2, Kim MS1, Kim EC1.
To elucidate the prevalence of cataract, glaucoma, pterygia, and diabetic retinopathy among Korean postmenopausal women with or without estrogen replacement therapy (ERT).
A cross-sectional, nationally representative sample from the 4th Korea National Health and Nutrition Examination Survey (KNHANES IV) (2007-2009) was used. Participants were interviewed for the determination of socioeconomic and gynecologic factors. Each woman also underwent an ophthalmologic examination and provided a blood sample for risk factor assessment.
Of 3968 postmenopausal women enrolled, 3390 had never received estrogen, and 578 were undergoing estrogen treatment. After adjusting for age, diabetes, hypertension, high cholesterol levels, and high low-density lipoprotein levels, the prevalence of anterior polar cataract, retinal nerve fiber layer (RNFL) defect, and flesh pterygium was higher in the non-ERT group (OR, 3.24; 95% CI, 1.12-9.35, OR 1.70; 95% CI, 1.04-2.78, OR 3.725; 95% CI, 1.21-11.45, respectively). Further, the prevalence of atrophic pterygium was lower in the non-ERT group compared to that in the ERT group (OR, 0.21, 95% CI, 0.07-0.63).
These data suggest that ERT has a protective effect against the development of anterior polar cataract, flesh pterygium, and RNFL defect.
The source of the experiencePubMed
Concepts, symbols and science items
Activities and commonsteps
Eye disease treatments
Eye disease treatments - glaucoma
Eye disease treatments - macular degeneration
SuppressionsBlindness, macular degeneration and other sight impairment